Then, the survival analysis displayed a high expression of FDX1 was a poor prognostic factor for all WHO grade survival in primary glioma (p < 0.0001) or recurrent glioma (p = 0.034) (Figure 8A). Here, FDX1 is linked to central nervous system cancer.